CY1124677T1 - (1s,4s)-4-(2-(((3s,4r)-3-φθoροtetpaϋδpo-2h-πypan-4-yλ)amino)-8-((2,4,6-τριχλωροφαινυλ)αμινο)-9η-πουριν-9-υλ)-1-μεθυλοκυκλοεξανο-1-καρβοξαμιδιο και μεθοδοι χρησης αυτου - Google Patents
(1s,4s)-4-(2-(((3s,4r)-3-φθoροtetpaϋδpo-2h-πypan-4-yλ)amino)-8-((2,4,6-τριχλωροφαινυλ)αμινο)-9η-πουριν-9-υλ)-1-μεθυλοκυκλοεξανο-1-καρβοξαμιδιο και μεθοδοι χρησης αυτουInfo
- Publication number
- CY1124677T1 CY1124677T1 CY20211100932T CY211100932T CY1124677T1 CY 1124677 T1 CY1124677 T1 CY 1124677T1 CY 20211100932 T CY20211100932 T CY 20211100932T CY 211100932 T CY211100932 T CY 211100932T CY 1124677 T1 CY1124677 T1 CY 1124677T1
- Authority
- CY
- Cyprus
- Prior art keywords
- carboxamide
- methods
- methylocyclohexane
- purine
- amino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Παρέχονται στο παρόν σκευάσματα, στερεές μορφές και μέθοδοι χρήσης που σχετίζονται με (1s,4s)-4-(2-(((3S,4R)-3-φθοροτετραϋδρο-2Η-πυραν-4-υλ)αμινο)-8-((2,4,6-τριχλωροφαινυλ)αμινο)-9Η-πουριν-9-υλ)-1-μεθυλκυκλοεξανο-1-καρβοξαμίδιο.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662317468P | 2016-04-01 | 2016-04-01 | |
PCT/US2017/025289 WO2017173218A1 (en) | 2016-04-01 | 2017-03-31 | Solid forms of (1s,4s)-4-(2-(((3s4r)-3-fluorotetrahydro-2h-pyran-4-yl) amino)-8-((2,4,6-trichlorophenyl) amino)-9h-purin-9-yl)-1-methylcyclohexane-1-carboxamide and methods of their use |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1124677T1 true CY1124677T1 (el) | 2022-07-22 |
Family
ID=59960229
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20211100932T CY1124677T1 (el) | 2016-04-01 | 2021-10-27 | (1s,4s)-4-(2-(((3s,4r)-3-φθoροtetpaϋδpo-2h-πypan-4-yλ)amino)-8-((2,4,6-τριχλωροφαινυλ)αμινο)-9η-πουριν-9-υλ)-1-μεθυλοκυκλοεξανο-1-καρβοξαμιδιο και μεθοδοι χρησης αυτου |
Country Status (18)
Country | Link |
---|---|
US (2) | US10047090B2 (el) |
EP (2) | EP3845536A1 (el) |
JP (1) | JP6995058B2 (el) |
CN (1) | CN109819649B (el) |
AU (1) | AU2017240050B2 (el) |
CA (1) | CA3019105A1 (el) |
CY (1) | CY1124677T1 (el) |
DK (1) | DK3436019T3 (el) |
ES (1) | ES2895419T3 (el) |
HR (1) | HRP20211546T1 (el) |
HU (1) | HUE056631T2 (el) |
LT (1) | LT3436019T (el) |
MX (1) | MX2018011970A (el) |
PL (1) | PL3436019T3 (el) |
PT (1) | PT3436019T (el) |
RS (1) | RS62496B1 (el) |
SI (1) | SI3436019T1 (el) |
WO (1) | WO2017173218A1 (el) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201629063A (zh) | 2014-10-06 | 2016-08-16 | 標誌製藥公司 | 經取代胺基嘌呤化合物、其組合物及用其之治療方法 |
BR112018070163A2 (pt) * | 2016-04-01 | 2019-01-29 | Signal Pharm Llc | compostos de aminopurina substituída, composições e métodos de tratamento |
US10604537B2 (en) * | 2016-06-21 | 2020-03-31 | Teva Pharmaceuticals International Gmbh | Solid state forms of ixazomib citrate |
US10543214B2 (en) | 2017-10-04 | 2020-01-28 | Celgene Corporation | Compositions and methods of use of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamide |
EP3692041A1 (en) * | 2017-10-04 | 2020-08-12 | Celgene Corporation | Processes for the preparation of cis-4 [2-{(3s.4r)-3-fluorooxan-4-yl]amino)-8-(2,4,6-trichloroanilino)-9h-purin-9-yl]-1-methylcyclohexane-1-carboxamide |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5391485A (en) | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
JPS63500636A (ja) | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするdna |
US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
IL99699A (en) | 1990-10-10 | 2002-04-21 | Autoimmune Inc | Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes |
FI109088B (fi) | 1997-09-19 | 2002-05-31 | Leiras Oy | Tabletti ja menetelmä sen valmistamiseksi |
US7723340B2 (en) | 2005-01-13 | 2010-05-25 | Signal Pharmaceuticals, Llc | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
US7759342B2 (en) | 2005-01-13 | 2010-07-20 | Signal Pharmaceuticals, Llc | Methods of treatment and prevention using haloaryl substituted aminopurines |
US7521446B2 (en) | 2005-01-13 | 2009-04-21 | Signal Pharmaceuticals, Llc | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
JP2009516707A (ja) | 2005-11-18 | 2009-04-23 | アストラゼネカ・アクチエボラーグ | 固形製剤 |
JO3235B1 (ar) | 2006-05-26 | 2018-03-08 | Astex Therapeutics Ltd | مركبات بيررولوبيريميدين و استعمالاتها |
RU2496780C2 (ru) | 2006-10-27 | 2013-10-27 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Твердые формы |
EP2279731B1 (en) | 2008-04-23 | 2012-12-12 | Farmasierra Manufacturing, S.L. | Improved pharmaceutical composition containing ibuprofen and codeine |
WO2011071491A1 (en) | 2009-12-09 | 2011-06-16 | Signal Pharmaceuticals, Llc | Isotopologues of 4-[9-(tetrahydro-furan-3-yl)-8-(2, 4, 6- trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol |
US8603527B2 (en) * | 2010-10-25 | 2013-12-10 | Signal Pharmaceuticals, Llc | Pharmaceutical formulations of a substituted diaminopurine |
US8680076B2 (en) * | 2010-10-25 | 2014-03-25 | Signal Pharmaceuticals, Llc | Methods of treatment, improvement and prevention using haloaryl substituted aminopurines |
US9466042B2 (en) | 2012-01-24 | 2016-10-11 | International Business Machines Corporation | Facilitating the design of information technology solutions |
US20160082015A1 (en) | 2013-04-18 | 2016-03-24 | President And Fellows Of Harvard College | Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders |
GB201321737D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
TW201629063A (zh) * | 2014-10-06 | 2016-08-16 | 標誌製藥公司 | 經取代胺基嘌呤化合物、其組合物及用其之治療方法 |
BR112018070163A2 (pt) | 2016-04-01 | 2019-01-29 | Signal Pharm Llc | compostos de aminopurina substituída, composições e métodos de tratamento |
-
2017
- 2017-03-31 SI SI201730930T patent/SI3436019T1/sl unknown
- 2017-03-31 CA CA3019105A patent/CA3019105A1/en active Pending
- 2017-03-31 EP EP20212433.5A patent/EP3845536A1/en active Pending
- 2017-03-31 MX MX2018011970A patent/MX2018011970A/es unknown
- 2017-03-31 HR HRP20211546TT patent/HRP20211546T1/hr unknown
- 2017-03-31 EP EP17776743.1A patent/EP3436019B1/en active Active
- 2017-03-31 ES ES17776743T patent/ES2895419T3/es active Active
- 2017-03-31 RS RS20211323A patent/RS62496B1/sr unknown
- 2017-03-31 LT LTEPPCT/US2017/025289T patent/LT3436019T/lt unknown
- 2017-03-31 PT PT177767431T patent/PT3436019T/pt unknown
- 2017-03-31 AU AU2017240050A patent/AU2017240050B2/en active Active
- 2017-03-31 JP JP2018551324A patent/JP6995058B2/ja active Active
- 2017-03-31 DK DK17776743.1T patent/DK3436019T3/da active
- 2017-03-31 WO PCT/US2017/025289 patent/WO2017173218A1/en active Application Filing
- 2017-03-31 HU HUE17776743A patent/HUE056631T2/hu unknown
- 2017-03-31 PL PL17776743T patent/PL3436019T3/pl unknown
- 2017-03-31 CN CN201780032755.1A patent/CN109819649B/zh active Active
- 2017-03-31 US US15/475,836 patent/US10047090B2/en active Active
-
2018
- 2018-07-05 US US16/027,503 patent/US10513519B2/en active Active
-
2021
- 2021-10-27 CY CY20211100932T patent/CY1124677T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP3436019B1 (en) | 2021-07-28 |
EP3845536A1 (en) | 2021-07-07 |
EP3436019A1 (en) | 2019-02-06 |
JP2019515889A (ja) | 2019-06-13 |
CN109819649A (zh) | 2019-05-28 |
AU2017240050B2 (en) | 2021-12-16 |
CA3019105A1 (en) | 2017-10-05 |
US20180362529A1 (en) | 2018-12-20 |
AU2017240050A1 (en) | 2018-10-11 |
US10047090B2 (en) | 2018-08-14 |
CN109819649B (zh) | 2023-02-28 |
PT3436019T (pt) | 2021-11-04 |
EP3436019A4 (en) | 2019-08-28 |
DK3436019T3 (da) | 2021-10-11 |
LT3436019T (lt) | 2021-10-25 |
HRP20211546T1 (hr) | 2022-01-07 |
HUE056631T2 (hu) | 2022-02-28 |
WO2017173218A1 (en) | 2017-10-05 |
PL3436019T3 (pl) | 2022-01-10 |
US20170283418A1 (en) | 2017-10-05 |
SI3436019T1 (sl) | 2021-12-31 |
ES2895419T3 (es) | 2022-02-21 |
RS62496B1 (sr) | 2021-11-30 |
JP6995058B2 (ja) | 2022-02-21 |
US10513519B2 (en) | 2019-12-24 |
MX2018011970A (es) | 2019-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1124677T1 (el) | (1s,4s)-4-(2-(((3s,4r)-3-φθoροtetpaϋδpo-2h-πypan-4-yλ)amino)-8-((2,4,6-τριχλωροφαινυλ)αμινο)-9η-πουριν-9-υλ)-1-μεθυλοκυκλοεξανο-1-καρβοξαμιδιο και μεθοδοι χρησης αυτου | |
CY1124834T1 (el) | Αναστολεις της αλληλεπιδρασης της μηνινης-mll | |
EA202090090A1 (ru) | Включение неприродных нуклеотидов и способы с ними | |
CY1123259T1 (el) | Αντισωματα anti-pvrig και μεθοδοι χρησης | |
CY1121197T1 (el) | Il2rbhta/koinhς γαμμα αλυσου αντισωματα | |
CY1120517T1 (el) | Διαρυλικες ενωσεις χρησιμες για την αγωγη ανθρωπινων νοσων στην ογκολογια, νευρολογια και ανοσολογια | |
MA49093B1 (fr) | 4-amino-6-(hétérocycliques)picolinates et 6-amino-2-(hétérocyclique)pyrimidine-4-carboxylates et leur utilisation en tant qu'herbicides | |
BR112019007369A2 (pt) | anticorpos anti-lag-3 e métodos de uso dos mesmos | |
CY1121997T1 (el) | Κρυσταλλικες μορφες του 2-((4s)-6-(4-χλωροφαινυλ)-1-μεθυλ-4η-βενζο[c]ισοξαζολo[4,5-ε]αζεπιν-4-υλ)ακεταμιδιου | |
CL2019002605A1 (es) | Formulaciones que contienen proteínas de unión pd-1 y métodos de fabricación de las mismas. | |
CY1122613T1 (el) | Παραγωγα 4-οξο-3,4-διυδρο-1,2,3-βενζοτριαζινης ως ρυθμιστες toy gpr139 | |
MA39248B1 (fr) | Anticorps anti-jagged1 et procédés d'utilisation correspondants | |
CY1122957T1 (el) | 1η-πυραζολο[4,3-β]πυριδινες ως αναστολεις ρdε1 | |
CY1121187T1 (el) | Ενα εκχυλισμα απο indigo naturalis και μια διεργασια για την παρασκευη εκεινου | |
CY1123267T1 (el) | Κρυσταλλικες μορφες 2-(tpit-boytyλamino)-4-((1r,3r,4r)-3-yδpoξy-4-μεθυλοκυκλοεξυλαμινο)-πυριμιδινο-5-καρβοξαμιδιου | |
CL2020002597A1 (es) | Métodos para preparar composiciones proteicas estables | |
CY1121171T1 (el) | Πυρογλουταμικη βορτιοξετινη | |
CY1125014T1 (el) | Υποκατεστημενα παραγωγα ξανθινης | |
CY1124748T1 (el) | Φαρμακευτικες συνθεσεις που περιεχουν δοραβιρινη, φουμαρικη δισοπροξιλη τενοφοβιρης και λαμιβουδινη | |
CL2019001053A1 (es) | Formulaciones farmacéuticas y métodos para prepararlas. | |
DOP2016000202A (es) | Proteínas de fusión uti | |
CY1121105T1 (el) | Φαρμακοτεχνικη μορφη αταζαναβιρης και κομπισιστατης για θεραπεια hiv | |
CL2023000892A1 (es) | Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b (divisional). | |
CL2019002729A1 (es) | Formulaciones de ácido 1-amino-1-ciclopropanocarboxílico. | |
BR112018009627A2 (pt) | compostos contendo enxofre como solventes |